Amikatsin-Vista – antibacterial agent for system application for treatment of the infections caused by the strains of microorganisms, sensitive to amikacin, resistant to other aminoglycosides.

Structure

• active ingredient: amikacin;
contains
• 1 ml of solution amikacin of sulfate it is equivalent to amikacin of 250 mg; other components: sodium citrate, sodium metabisulphite, water for injections, sulphuric acid (10 N).

Contraindication

• renal failure;
• neuritis of an acoustical nerve;
• hypersensitivity to amikacin or to any other antibiotic of aminoglikozidny group and their derivatives;
• hypersensitivity to any of the excipients which are a part of medicine;
• myasthenia gravis;
• dysfunction of a vestibular mechanism;
• an azotemia (residual nitrogen is higher than 150 mg of %);
• preliminary treatment from - or nephrotoxic medicines.

Side reactions

Infection and invasion: superinfection or colonization by resistant bacteria or barmy mushrooms.

from the immune system: anaphylactic reactions, including an acute anaphylaxis, anaphylactoid reactions, reactions of hypersensitivity.

from a digestive tract: nausea, vomiting, abnormal liver function (increase in activity of hepatic Transaminases, hyperbilirubinemia).

from the system of blood formation: anemia, leukopenia, granulocytopenia, thrombocytopenia, hamaturia, eosinophilia.

from organs of sight: blindness, retina heart attack.

from a cardiovascular system: vasculitis, arterial hypotension.

from nervous system: a headache, drowsiness, neurotoxic action (twitching of muscles, feeling of numbness, pricking, epileptic attacks), decrease in hearing, vestibular frustration, dizziness, paresthesias, a tremor, spasms, encephalopathy is possible; in rare instances - violation of neuromuscular conductivity, emergence of neuromuscular blockade (muscular paralysis, respiratory depression) is possible.

from sense bodys: ototoxicity (relative deafness, decrease in hearing, sonitus, vestibular labyrinth violations, partially reversible or irreversible deafness), toxic action on a vestibular mechanism (diskoordination of movements, dizziness, nausea, vomiting).

Route of administration

to Apply amikacin whist intramusculary or intravenously. Usual doses for children of 12 years and adults - on 5 mg/kg of body weight each 8 hours or on 7.5 mg/kg of body weight each 12 hours. The maximum dose for adults – 15 mg/kg of body weight a day. In hard cases and at the infections caused by Pseudomonas to distribute a daily dose on 3 introductions. The maximum daily dose — 1.5 g. The maximum course dose should not exceed 15 g. Treatment duration usually is 3–7 days at intravenous administration and 7–10 days at intramuscular. To appoint the premature newborn in an initial dose 10 mg/kg of body weight, and then each 18–24 h on 7.5 mg/kg of body weight within 7–10 days. To the full-term newborn and children up to 12 years at first to appoint 10 mg/kg of body weight, then — 7.5 mg/kg of body weight each 12 hours within 7–10 days.

can apply the following solvents To introduction: 0.9% solution of sodium of chloride, 5% the glucose solution, lactat Ringera solution for injections containing glucose (5%).

Safety of use of amikacin during pregnancy is not established to

Feature of application

yet. Should appoint amikacin pregnant women and newborns only at urgent need and under fixed observation of the doctor.

Amikacin is allocated to

in breast milk. It is necessary to make the decision on the termination of breastfeeding or phase-out of medicine.

Children

apply Medicine in pediatric practice.

Amikatsin-Vista with care to treatment of the premature and full-term babies as because of an underdevelopment of a secretory system the removal of aminoglycosides can be extended, causing toxicity.

Ability to influence speed of response at control of motor transport or other mechanisms

Experience of use of amikacin demonstrates that it does not affect ability to drive the car or to work with mechanisms, but it is necessary to consider the probability of such side effects from central nervous system as drowsiness, violation of neuromuscular transfer.

Overdose

Symptoms. Emergence from - and nephrotoxic effect of medicine and signs of neuromuscular blockade is possible: sonitus, acoustical frustration, skin rash, a headache, dizziness, fever, paresthesias, depression of function of kidneys (to a renal failure), oppression or paralysis of breath, toxic reactions (an ataxy, disorders of urination, thirst, a loss of appetite, nausea, vomiting).

Treatment: if necessary medicine is brought out of an organism by parenteral dialysis or a hemodialysis. Reduce medicine level continuous arteriovenous haemo filtration. Also apply an exchange hemotransfusion to removal of medicine from an organism at newborns. At the first signs of blockade of neuromuscular conductivity it is necessary to stop

a niya of amikacin of sulfate and to immediately enter intravenously solution of Calcii chloridum or subcutaneously solution of a prozerin and atropine. In need of the patient transfer to the managed breath.

Interaction with other medicines and other types of interactions

Pharmaceutical it is incompatible with penicillin, heparin, cephalosporin, kapreomitsiny, Amphotericinum B, a hydrochlorothiazide, erythromycin, nitrofurantoin, vitamins of group B and C, potassium chloride.

Amikatsin-Vista is shown by synergism in interaction with karbenitsilliny, benzylpenicillin, cephalosporins (at patients with heavy chronic kidney disease at simultaneous application with β-lactat antibiotics the decrease in efficiency of aminoglycosides is possible).

Storage conditions

For medicine does not need special storage conditions. To store out of children's reach.